

The Canadian National Stock Exchange has not approved nor disapproved the contents of this press release.

## MERUS LABS INTERNATIONAL INC.

MERUS LABS INTERNATIONAL INC. ANNOUNCES STOCK OPTION GRANT

VANCOUVER, June 28, 2011

(CNSX: MR)

**Merus Labs International Inc.** ("Merus") announces the grant on June 27, 2011 of incentive stock options to purchase 100,000 common shares of Merus at a price of \$0.75 per common share until June 27, 2013 to Moira Ong, Chief Financial Officer of Merus.

### **About Merus Labs International Inc.**

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

### **Forward-looking Statements:**

*This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with securities regulatory authorities.*

For further information please contact:

Dr. Ahmad Doroudian, Chief Executive Officer  
Merus Labs International Inc.  
Tel: (604) 805-7783  
[adoroudian@meruslabs.com](mailto:adoroudian@meruslabs.com)